Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Hypericin

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Reaches Enrollment Milestone In Phase 3 Trial
    Soligenix Reaches Enrollment Milestone In Phase 3 Trial

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-achieves-enrollment-milestone-for-planned-interim-analysis-in-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302619926.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share
    Soligenix Refreshes US Medical Advisory Board For Lymphoma
    Soligenix Refreshes US Medical Advisory Board For Lymphoma

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-302582841.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302576600.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    Soligenix Manufactures Synthetic Hypericin at Sterling Pharma
    Soligenix Manufactures Synthetic Hypericin at Sterling Pharma

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-synthetic-hypericin-successfully-manufactured-at-sterling-pharma-solutions-302495267.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hybryte-clinical-results-demonstrate-continued-improvement-post-treatment-302317457.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma

    09 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/expanded-hybryte-treatment-demonstrating-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma-302190262.html

    PR NEWSWIRE
    09 Jul 2024
    Share Share